DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration Rockville MD 20857

The Honorable John D. Dingell
Chairman
Committee on Energy and Commerce
House of Representatives
Washington, D.C. 20515-6115

FEB 1 4 2008

Dear Mr. Chairman:

Thank you for your letter of January 22, 2008, co-signed by Chairman Bart Stupak, Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, requesting certain documents related to advertisements for Lipitor.

Information contained in the enclosures may include information that is trade secret, commercial confidential or other information protected from disclosure to the public under the Freedom of Information Act (Title 5, *United States Code* [U.S.C.] 552), the Trade Secrets Act (18 U.S.C. 1905), the Privacy Act (5 U.S.C. 552a), and Food and Drug Administration (FDA or the Agency) regulations. The Committee should not publish or otherwise make public any such information. We would be glad to discuss with the Committee staff the protected status of any specific information.

We have repeated your request below, followed by our response.

Provide all records relating to any print, radio, television, or internet advertisements for Lipitor that involve Dr. Jarvik. These records are to include, but not be limited to, any records relating to the review or monitoring of said advertisements, complaints received relating to these advertisements, and any comments or consultations that DDMAC has provided relating to these advertisements.

We are sending one box of documents and thirteen disks responsive to this request.

Thank you again for your interest in this matter. If you have any further questions, please let us know. A similar letter has been sent to Chairman Stupak, without enclosures.

Sincerely,

stephen R. Mason

Acting Assistant Commissioner

for Legislation

Enclosures